A record of what Dipan Mehta said publicly, with the source. Not advice.
Pending — not yet graded
“Bullish on the Indian pharma sector, viewing it as attractive despite market volatility and tariff noise. The industry is diversified beyond the US, with strong performance in Europe and the domestic market. While uncertainty creates resistance, corrections offer good investment opportunities, and the sector's long-term outlook remains positive.”
Nifty PharmaBullishCalled 19 Feb 2025
This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.
Read the original articleSee Dipan Mehta’s full track record